Screener
Protagonist Therapeutics PTGX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:17 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091123
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Receivable from collaboration partner | 13,416 | 121 |
| Contract asset | 3,366 | — |
| Prepaid expenses and other current assets | 7,790 | 10,089 |
| Total current assets | 807,148 | 577,574 |
| Marketable securities - noncurrent | 66,875 | 78,638 |
| Property and equipment, net | 3,456 | 3,860 |
| Restricted cash - noncurrent | 287 | 287 |
| Operating lease right-of-use asset | 6,946 | 7,829 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Protagonist Therapeutics's total current assets?
- Protagonist Therapeutics (PTGX) reported total current assets of $807.15M in Q2 2026.
- How has Protagonist Therapeutics's total current assets changed year-over-year?
- Protagonist Therapeutics's total current assets increased by 34.0% year-over-year, from $602.53M to $807.15M.
- What is the long-term trend for Protagonist Therapeutics's total current assets?
- Over 5 years (2020 to 2025), Protagonist Therapeutics's total current assets has grown at a 12.8% compound annual growth rate (CAGR), from $315.61M to $577.57M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Protagonist Therapeutics's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude